Six benefits of Cloud Computing in the pharma industry

Immatics and Bristol Myers Squibb enter exclusive license for TCR Bispecific programme

Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales

Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn

The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases

Lupin’s Goa plant receives EIR from US FDA

FDA changes inspection classification of the facility to Voluntary Action Indicated

Trastuzumab Deruxtecan supplemental New Drug Application for breast cancer submitted in Japan

In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020

ICMR Dibrugarh designs kit to detect Omicron variant in two hours

GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model

Moderna announces positive interim Phase 1 data for mRNA flu vaccine

Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed

Govt. to organise Innovation Week to encourage startup ecosystem

The proposed week-long event will comprise specific themes - International engagements, market access and incubation support, funding support to startups etc. and will cover the different areas of the innovation lifecycle

Nova Nordisk to invest 17 bn Danish kroner to expand capacity in Denmark

The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity

Govt includes seven more companies under PLI scheme

Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs